Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans

March 30, 2026 - 00:03

Biotechnology company Halozyme Therapeutics has announced a key leadership transition, appointing David Ramsay as its interim Chief Financial Officer. The move comes as the firm continues to advance its growth initiatives in the biopharma sector.

Ramsay steps into the role with over three decades of extensive financial and operational experience, much of it within the life sciences industry. His background is expected to provide steady oversight of the company's financial strategy during this period of transition. The appointment is effective immediately, with Ramsay assuming the responsibilities while the board of directors conducts a search for a permanent CFO.

The leadership update occurs at a significant time for Halozyme, which is recognized for its proprietary ENHANZE drug delivery technology. This platform is designed to improve the absorption and efficacy of injected medicines, forming partnerships with numerous major pharmaceutical companies. Analysts have recently highlighted the company's potential, pointing to its technology portfolio and partnership-driven revenue model as foundations for sustained growth.

Company officials expressed confidence that Ramsay's deep industry expertise will ensure financial discipline and support ongoing business operations seamlessly. The focus remains on executing the company's strategic plans, which include expanding the reach of its ENHANZE technology and delivering value through its collaborative ventures. The search for a permanent financial officer is underway, with the board committed to identifying a candidate who aligns with Halozyme's long-term objectives.